Altun, AUgur-Altun, BTatli, E2024-06-122024-06-1220040391-40971720-8386https://doi.org/10.1007/BF03346278https://hdl.handle.net/20.500.14551/1953413th European Congress on Obesity -- MAY 26-29, 2004 -- Prague, CZECH REPUBLICReceptor activator of nuclear factor kappaB (RANK) and osteoprotegerin (Cl represent the ligand and decoy receptor, respectively, of a pleiotropic cytokine system that regulates bone metabolism and vascular biology. Several studies supported systemic microvascular abnormalities in patients with cardiac syndrome X (CSX). This study investigates serum Cl levels in healthy obese subjects and healthy lean controls affected by cardiac syndrome X. Methods: We compared the Cl levels in 8 patients with cardiac syndrome X [2 males, 6 females; age: 46 +/- 6 yr; body mass index (BMI): 30 +/- 5 kg/m(2)] with 24 obese subjects (8 males, 16 females; age: 38 +/- 5 yr; BMI: 35 +/- 5 kg/m(2)) and 15 healthy lean controls (6 males, 9 females; age: 36 +/- 5 yr; BMI: 23 +/- 2 kg/m(2); BMI<25kg/m(2)). Results: Serum Cl levels in patients with cardiac syndrome X were lower than those in obese subjects and lean controls (11..45 +/- 8.36 pg/ml, 14.78 +/- 8.22 pg/mI, 19.24 +/- 6.96 pg/ml, respectively, cardiac syndrome X vs lean controls, P = 0.039). Conclusions: Serum OPG levels are lower in patients with CSX. Further studies on the mechanisms of OPG in microangiopathy may help to evaluate the OPG system role as a marker for disease activity, prognosis and response to therapy in cardiovascular diseases. (C) 2004, Editrice Kurtis.en10.1007/BF03346278info:eu-repo/semantics/closedAccessCardiac Syndrome XOsteoprotegerinMicroangiopathyObesityNf-Kappa-BCoronary Flow VelocityMicrovascular AnginaRank LigandIncreaseReceptorPainConference Object279839843Q3WOS:0002259541000082-s2.0-1454428968015648548Q2